PREVENTION AND MANAGEMENT OF DUODENAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS

L A A Brosens, J J Keller, G J A Offerhaus, M Goggins, F M Giardiello


Familial adenomatous polyposis (FAP) is one of two well described forms of hereditary colorectal cancer. The primary cause of death from this syndrome is colorectal cancer which inevitably develops usually by the fifth decade of life. Screening by genetic testing and endoscopy in concert with prophylactic surgery has significantly improved the overall survival of FAP patients. However, less well appreciated by medical providers is the second leading cause of death in FAP, duodenal adenocarcinoma. This review will discuss the clinicopathological features, management, and prevention of duodenal neoplasia in patients with familial adenomatous polyposis.

FAMILIAL ADENOMATOUS POLYPOSIS

FAP is an autosomal dominant disorder caused by a germline mutation in the adenomatous polyposis coli (APC) gene. FAP is characterised by the development of multiple (>100) adenomas in the colorectum. Colorectal polyposis develops by age 15 years in 50% and age 35 years in 95% of patients. The lifetime risk of colorectal carcinoma is virtually 100% if patients are not treated by colectomy.1 Patients with FAP can also develop a wide variety of extraintestinal findings. These include cutaneous lesions (lipomas, fibromas, and sebaceous and epidermoid cysts), desmoid tumours, osteomas, occult radio-opaque jaw lesions, dental abnormalities, congenital hypertrophy of the retinal pigment epithelium, and nasopharyngeal angiofibroma. In addition, FAP patients are at increased risk for several malignancies, such as hepatoblastoma, pancreatic, thyroid, biliary-tree, and brain tumours.1

Other gastrointestinal manifestations commonly found in FAP patients are duodenal adenomas, and gastric fundic gland and adenomatous polyps. Of concern, duodenal cancer is the second leading cause of death after colorectal cancer in these individuals.

EPIDEMIOLOGY OF DUODENAL POLYPS AND CANCER

After the colorectum, the duodenum is the second most commonly affected site of polyp development in FAP (fig 1).2 3 Duodenal adenomas can be found in 30–70% of FAP patients2–4 and the lifetime risk of these lesions approaches 100%.4 5 Duodenal/periampullary adenocarcinoma is the leading cause of death in FAP after colorectal cancer.4 These patients have a 100–330-fold higher risk of duodenal cancer compared with the general population.2 4 Of note, duodenal cancer is rare in the population, with an incidence of 0.01–0.04%.9 Estimates of the cumulative risk of developing duodenal cancer in FAP range from 4% at age 70 years to 10% at age 60 years.10 11 Recently, a large prospective five nation study set the cumulative incidence rate of duodenal cancer at 4.5% by age 57 years. The median age of duodenal cancer development was 52 years (range 26–58).4

UPPER GASTROINTESTINAL POLYP DISTRIBUTION AND TYPE

Polyps can be found throughout the duodenum, but the second and third portion and the periampullary region are the most commonly affected sites. This pattern probably reflects exposure of duodenal mucosa to bile acids,12 suggesting a role for these compounds in duodenal carcinogenesis.33 Most polyps in the duodenum are adenomas whereas polyps in the stomach are usually benign non-adenomatous fundic gland lesions. However, approximately 10% of gastric polyps are adenomas.3 12 Interestingly, Japanese and Korean FAP patients have a 3–4 times higher risk of gastric cancer compared with the general population14 15 whereas no increased risk has been found in Western countries.8 Besides polypoid neoplasia, flat adenomas can be found in the duodenum of approximately 30% of FAP patients and careful follow up of these lesions is recommended.16

GENOTYPE-PHENOTYPE CORRELATION IN DUODENAL POLYPOSIS

The cause of FAP is germline mutation of the APC gene. The APC gene is a tumour suppressor gene with 15 exons that encodes a 2843 amino acid protein with a molecular weight of 309 kDa. One third of all germline mutations occur in codons 1061 and 1309 (fig 2).1
Several genotype-phenotype correlations for colonic polyposis in FAP have been established. Mutations between codon 1250 and codon 1464 are associated with profuse polyposis (>5000 colorectal polyps) and those in codon 1309 with early onset of adenoma development (10 years earlier) and colorectal cancer (age <35 years). Mutations at the 5' and 3' extremes of the APC gene cause attenuated FAP, characterised by oligopolyposis (less than 100 colorectal polyps) at presentation and later onset of colorectal cancer development (age >50 years).

The relationship between severity of duodenal polyposis and mutations in the APC gene is less well understood. Taken together, published reports are inconsistent (table 1). One study failed to detect a correlation between the site of mutation and the severity of duodenal polyposis. In another, severe duodenal polyposis was found in patients with 5' mutations. Still others correlate severe duodenal disease with mutations in the central part of the gene. However, most reports indicate that mutations in exon 15 of the APC gene, particularly distal to codon 1400, give rise to a severe duodenal phenotype.

CLASSIFICATION OF DUODENAL POLYPOSIS

The most useful system for rating the severity of duodenal polyposis was developed by Spigelman and colleagues. This classification describes five (0–IV) stages. Points are accumulated for number, size, histology, and severity of dysplasia of polyps (table 2). Stage I indicates mild disease whereas stages III–IV imply severe duodenal polyposis (fig 4). Approximately 70–80% of FAP patients have stage II or stage III duodenal disease, and 20–30% have stage I or stage IV disease. The estimated cumulative incidence of stage IV duodenal disease however is 50% at age 70 years.

Figure 2 Schematic representation of the adenomatous polyposis coli (APC) gene, consisting of 15 exons and 2843 codons. One third of all germline mutations occur in codons 1061 and 1309. Mutations at the extremes of the APC gene present as attenuated familial adenomatous polyposis.
Several investigators have shown that duodenal polyposis slowly progresses. One study followed 114 FAP patients for 51 months and found progression of polyps in size (26%), number (32%), and histology (11%).41 When individuals are followed for longer, duodenal polyps advance in Spigelman stage. Heiskanen and colleagues’ reported worsening polyposis in 73% of 71 FAP patients followed for 11 years. The median interval for progression by one stage was 4–11 years. Another group reported a stage change in 42% of patients with increasing severity of disease. Recommendations concerning the age of initiation of upper tract surveillance are not uniform. Some propose that screening for upper gastrointestinal disease should start at the time of FAP diagnosis.42 The NCCN (National Comprehensive Cancer Network), after review of all case reports of duodenal cancer in FAP patients, recommended a baseline upper gastrointestinal endoscopic examination at 25–30 years of age.43 Guidelines for continued endoscopic surveillance after baseline examination have been developed according to Spigelman stage by several authorities.44 In general, recommendations include stage 0 every 4 years; stage I every 2–3 years; stage II every 2–3 years; stage III every 6–12 months with consideration for surgery; and stage IV strongly consider surgery (table 3).

**Endoscopic treatment**

Endoscopic treatment options for duodenal lesions include snare excision, thermal ablation, argon plasma coagulation,
and photodynamic therapy (PDT). Most reports of endoscopic therapy use snare excision. However, duodenal adenomas are often flat non-polypoid structures and, therefore, difficult to remove using conventional snare excision. For these cases, prior submucosal saline/adrenaline infusion may facilitate removal and reduce the risk of haemorrhage and perforation.\(^{40}\) In addition, thermal ablation,\(^{54}\) argon plasma coagulation,\(^{47}\) or PDT\(^{48-51}\) may be suitable.

PDT is a non-thermal technique relying on the combined effect of a low power activating light and a photosensitising drug that is selectively retained within neoplastic tissue with minimal retention in surrounding normal tissue. Few reports of PDT for adenomas in the gastrointestinal tract exist. Loh and colleagues\(^{50}\) successfully applied PDT for resection of colorectal adenomas: 7/9 treated adenomas were eradicated. Others have used PDT for resection of neoplastic lesions in the upper gastrointestinal tract but results are disappointing (table 4).\(^{48\ 49\ 51}\)

Endoscopic treatment of duodenal neoplasia for Spigelman stage II and III polyposis has been pursued by some investigators. However, the benefit of this approach in eradicating duodenal polyposis is difficult to justify but may be useful in individual cases. Literature reports of endoscopic treatment for FAP patients with duodenal/ampullary polyps are summarised in table 4. These publications reveal that endoscopic treatment is usually insufficient to guarantee a polyp-free duodenum and fraught with complications. Recurrence rates of adenomatous tissue in duodenum of FAP patients treated endoscopically range from 50% to 100%.\(^{44\ 46\ 52\ 53}\) Lower recurrence was reported by Norton and colleagues\(^{54\ 55}\) but their study population also included patients with sporadic duodenal lesions. In

### Table 2: Spigelman classification for duodenal polyposis in familial adenomatous polyposis

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyp number</td>
<td>1–4</td>
</tr>
<tr>
<td>Polyp size (mm)</td>
<td>1–4</td>
</tr>
<tr>
<td>Histology</td>
<td>Tubular</td>
</tr>
<tr>
<td>Dysplasia</td>
<td>Mild</td>
</tr>
</tbody>
</table>

Stage 0, 0 points; stage I, 1–4 points; stage II, 5–6 points; stage III, 7–8 points; stage IV, 9–12 points.

<table>
<thead>
<tr>
<th>Spigelman stage</th>
<th>Endoscopic frequency</th>
<th>Chemoprevention</th>
<th>Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>4 years</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Stage I</td>
<td>2–3 years</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Stage II</td>
<td>2–3 years</td>
<td>+/-</td>
<td>No</td>
</tr>
<tr>
<td>Stage III</td>
<td>6–12 months</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>Stage IV</td>
<td>6–12 months</td>
<td>+/-</td>
<td>Yes</td>
</tr>
</tbody>
</table>

### Table 3: Recommendations for management of duodenal polyposis in familial adenomatous polyposis, adjusted to the Spigelman stage of duodenal polyposis

### Figure 4: Spigelman stages of duodenal polyposis. (A) Stage I. (B) Stage II. (C) Stage III. (D) Stage IV.
Summary, endoscopic treatment appears useful in individual cases but follow up remains necessary and surgical intervention is often indicated in patients with more severe polyposis.

**Surgery**

Surgical options utilised to treat duodenal polyposis include local surgical treatment (duodenotomy with polypectomy and/or ampullectomy), pancreas and pylorus sparing duodenectomy, and pancreaticoduodenectomy. There are no randomised studies published to help guide surgical selection.

Publications of local surgical treatment with duodenotomy for duodenal polyposis in FAP patients are summarised in Table 5. This surgery has proven insufficient to guarantee a cure and, although this appears to lack of statistical power. However, a second evaluation of this surgery was not significant, possibly due to the lack of statistical power. In the final analysis, the morbidity and mortality of these surgeries must be weighed against the risk of developing duodenal adenocarcinoma.

**Pharmacological treatment**

Non-steroidal anti-inflammatory drugs (NSAIDs) regress colorectal adenomas in FAP patients. The value of these agents for duodenal polyposis regression is unclear. Studies of duodenal adenoma regression have primarily utilised sulindac (NSAID) and selective COX-2 inhibitors (table 7). Nugent and colleagues compared the effect of sulindac (n = 12) and placebo (n = 12) on the number of duodenal polyps. Polyp number decreased in five patients after six months of treatment and was unchanged in five after six months of treatment. The difference between sulindac and placebo treated patients was not significant, possibly due to the lack of statistical power. However, a second evaluation of endoscopic videostapes from this cohort revealed a statistically significant effect on small (<2 mm) duodenal polyps whereas larger (≥3 mm) duodenal polyps were unaffected.

Another randomised crossover trial that compared sulindac

---

**Table 4** Endoscopic treatment for duodenal neoplastic lesions

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment</th>
<th>Follow up</th>
<th>Patients</th>
<th>Outcome</th>
<th>Postoperative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soravia</td>
<td>Endoscopic resection</td>
<td>4–34 months (mean 18)</td>
<td>6 FAP</td>
<td>Recurrence of duodenal adenomas in all 5 surviving patients</td>
<td>1 patient died of acute pancreatitis after endoscopic ampullectomy</td>
</tr>
<tr>
<td>Bertoni</td>
<td>Snare papillotomy</td>
<td>18 months</td>
<td>2 FAP</td>
<td>Recurrence in 1 patient, successfully retreated</td>
<td>No postoperative complications</td>
</tr>
<tr>
<td>Marpuro</td>
<td>Snare polypectomy (3)</td>
<td>6–24 months (mean 19)</td>
<td>5 FAP</td>
<td>Recurrence in 3 patients</td>
<td>No postoperative complications</td>
</tr>
<tr>
<td>Alarcon</td>
<td>Snare polypectomy and thermal contact ablation</td>
<td>14–83 months (mean 43.5)</td>
<td>3 FAP</td>
<td>Recurrence in 3 patients</td>
<td>NS</td>
</tr>
<tr>
<td>Heiskanen</td>
<td>Snare excision (5), YAG laser coagulation (1)</td>
<td>0.4–15.1 years (median 6.8)</td>
<td>6 FAP</td>
<td>No significant difference in Spigelman stage preoperative and at latest endoscopy</td>
<td>Patient treated with YAG laser developed mild pancreatitis</td>
</tr>
<tr>
<td>Norton</td>
<td>Ampullary ablative therapy</td>
<td>1–134 months (median 24)</td>
<td>59 FAP, 32 sporadic</td>
<td>Return to normal histology in 44% of sporadic and 34% of FAP lesions</td>
<td>12 patients had mild complications, 3 severe complications: 1 duodenal stenosis, 1 postcoagulation syndrome, 1 necrotising pancreatitis</td>
</tr>
<tr>
<td>Norton</td>
<td>Snare excision of papilla</td>
<td>2–32 months (median 9)</td>
<td>15 FAP, 11 sporadic</td>
<td>Recurrence rate of adenomatous tissue of 10%</td>
<td>2 minor bleedings, 4 mild pancreatitis, 1 duodenal perforation</td>
</tr>
<tr>
<td>Milky</td>
<td>PDT with ALA or Photofrin</td>
<td>28 months (median 9)</td>
<td>4 FAP patients with duodenal polyps</td>
<td>Superficial necrosis and no polyp reduction after PDT with ALA. Deep necrosis and moderate polyp reduction after PDT using Photofrin.</td>
<td>Mild skin photosensitivity using Photofrin</td>
</tr>
<tr>
<td>Regula</td>
<td>PDT with ALA</td>
<td>2 duodenal adenomas, 3 ampullary carcinomas</td>
<td>2 duodenal adenomas,</td>
<td>Superficial necrosis of adenomas and in 2 adenocarcinomas. 1 adenocarcinoma unaffected</td>
<td>Side effects included mild skin photosensitivity, nausea/vomiting, and transient increases in ASAT</td>
</tr>
<tr>
<td>Loh</td>
<td>PDT with Hpd or Photofrin</td>
<td>3–50 months (median 5.5)</td>
<td>8 patients with 9 colorectal adenomas</td>
<td>7 adenomas successfully eradicated</td>
<td>No local complications</td>
</tr>
<tr>
<td>Abuaf</td>
<td>PDT with Hpd</td>
<td></td>
<td>10 patients with ampullary carcinoma unsuitable for surgery</td>
<td>Remission for 8–12 months in 3 patients with small tumours. In 4 patients with small tumours bulk was reduced. No improvement in patients with extensive disease</td>
<td>3 patients with moderate skin sensitisation</td>
</tr>
</tbody>
</table>

NS, not stated; PDT, photodynamic therapy; ALA, 5-aminolaevulinic acid; Hpd, haematoporphyrin derivative or Photofrin; FAP, familial adenomatous polyposis.
Table 5  Local surgical treatment (duodenotomy with polypectomy and/or ampullectomy) for duodenal neoplastic lesions

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment</th>
<th>Follow up</th>
<th>Patients</th>
<th>Outcome</th>
<th>Postoperative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soravia³³</td>
<td>Duodenotomy with polypectomy (1) or ampullectomy (4)</td>
<td>4–34 months (mean 18)</td>
<td>5 FAP</td>
<td>Recurrence in 4 patients. 1 patient died of cancer</td>
<td>1 transient duodenal fistula</td>
</tr>
<tr>
<td>Morpurgo⁴⁴</td>
<td>Transduodenal ampullectomy (1) or polyp excision (1)</td>
<td>6–24 months (mean 19)</td>
<td>2 FAP</td>
<td>Recurrence in 1 patient</td>
<td>1 severe pancreatitis</td>
</tr>
<tr>
<td>Alarcon⁴⁶</td>
<td>Local resection</td>
<td>8–33 months (mean 20.2)</td>
<td>5 FAP</td>
<td>Recurrence in 4 patients. 1 had progressive metastatic adenocarcinoma</td>
<td>NS</td>
</tr>
<tr>
<td>Heiskanen⁵⁵</td>
<td>Duodenotomy</td>
<td>0.4–15.1 years (median 6.8)</td>
<td>15 FAP</td>
<td>No significant difference in Spigelman stage preoperative and at latest endoscopy</td>
<td>No postoperative complications</td>
</tr>
<tr>
<td>Penna⁶⁶</td>
<td>Duodenotomy with polypectomy (1) or ampullectomy (4)</td>
<td>5–36 months (mean 13.3)</td>
<td>12 FAP</td>
<td>Recurrence in 12 patients</td>
<td>NS</td>
</tr>
<tr>
<td>Penna⁶⁶</td>
<td>Duodenotomy with polypectomy (1) or ampullectomy (4)</td>
<td>36–72 months (mean 53)</td>
<td>6 FAP</td>
<td>Recurrence in 6 patients</td>
<td>1 cholecystectomy for cholecystitis, 2 duodenal fistulas</td>
</tr>
<tr>
<td>de Vos tot</td>
<td>Duodenotomy with polypectomy (1) or ampullectomy (4)</td>
<td>4–13 months (mean 11)</td>
<td>8 FAP</td>
<td>Recurrence in 6 patients</td>
<td>1 minor morbidity*</td>
</tr>
<tr>
<td>de Vos tot</td>
<td>Duodenotomy with polypectomy (1) or ampullectomy (4)</td>
<td>5–103 months (mean 29)</td>
<td>22 FAP</td>
<td>Recurrence in 17 patients. 1 death from metastatic disease</td>
<td>1 minor morbidity*</td>
</tr>
<tr>
<td>Ruo⁶⁶</td>
<td>Duodenotomy with polypectomy (1) or ampullectomy (4)</td>
<td>35 months</td>
<td>1 FAP</td>
<td>Gastric cancer arising from a polyp at 35 months</td>
<td>No postoperative complications</td>
</tr>
<tr>
<td>Farnell⁶⁶</td>
<td>Transduodenal local excision</td>
<td>10 years</td>
<td>53 sporadic and FAP patients</td>
<td>Recurrence rate of 32% at 5 years and 43% at 10 years of follow up</td>
<td>3 pancreatitis, 3 leaks, 2 delayed gastric emptying, 2 ileus, 1 fluid overload</td>
</tr>
</tbody>
</table>

*That is, wound infection, atelectasis, or urinary tract infection. NS, not stated; FAP, familial adenomatous polyposis.

Table 6  Pancreaticoduodenectomy and pylorus or pancreas preserving duodenectomy for duodenal neoplastic lesions

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment</th>
<th>Follow up</th>
<th>Patients</th>
<th>Outcome</th>
<th>Postoperative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soravia³³</td>
<td>Pancreaticoduodenectomy</td>
<td>NS</td>
<td>1 FAP</td>
<td>Unknown</td>
<td>NS</td>
</tr>
<tr>
<td>Morpurgo⁴⁴</td>
<td>Pancreaticoduodenectomy</td>
<td>NS</td>
<td>4 FAP</td>
<td>No recurrence reported</td>
<td>Increased number of bowel movements. One patient required patch excision and end ileostomy to control diarrhea. 3 patients experienced weight loss, 1 patients had episodes of pancreatitis</td>
</tr>
<tr>
<td>Alarcon⁴⁶</td>
<td>Pancreaticoduodenectomy</td>
<td>40–50 months (mean 45.7)</td>
<td>3 FAP</td>
<td>No recurrence. Two of three patients had a small tubular adenoma in the duodenal bulb. No recurrence in patients treated for severe duodenal polyposis.</td>
<td>1 pancreatic fistula, 1 upper GI haemorrhage</td>
</tr>
<tr>
<td>Penna⁶⁶</td>
<td>Pancreaticoduodenectomy</td>
<td>9–108 months (mean 42)</td>
<td>7 FAP</td>
<td>Severe duodenal polyposis</td>
<td>1 minor morbidity*, 12 major morbidity†, 1 patient died of postoperative complications</td>
</tr>
<tr>
<td>de Vos tot</td>
<td>Pancreaticoduodenectomy</td>
<td>7–96 months (mean 47)</td>
<td>23 FAP</td>
<td>Recurrence in 3, 6 died of metastatic disease</td>
<td>1 minor morbidity*, 3 major morbidity†</td>
</tr>
<tr>
<td>de Vos tot</td>
<td>Pancreaticoduodenectomy</td>
<td>2–15 months (mean 11)</td>
<td>6 FAP</td>
<td>No recurrence</td>
<td></td>
</tr>
<tr>
<td>de Vos tot</td>
<td>Pancreaticoduodenectomy</td>
<td>7–93 months (mean 45)</td>
<td>12 FAP</td>
<td>Recurrence in 3 of 9, 3 died of metastatic disease</td>
<td>1 minor morbidity*, 4 major morbidity†</td>
</tr>
<tr>
<td>Ruo⁶⁶</td>
<td>Pancreaticoduodenectomy</td>
<td>37–162 months (mean 70.5)</td>
<td>7 FAP</td>
<td>1 patient developed jejunal adenomas 12 years after operation</td>
<td>1 patient developed pancreatic ascites</td>
</tr>
<tr>
<td>Chung⁷¹</td>
<td>Pancreaticoduodenectomy</td>
<td>0.5–3 years (mean 2.1)</td>
<td>4 FAP</td>
<td>No recurrence</td>
<td>1 gastric retention, 1 pancreatic fistula</td>
</tr>
<tr>
<td>Kalady⁶²</td>
<td>Pancreaticoduodenectomy</td>
<td>10 years</td>
<td>3 FAP</td>
<td>1 had polyp recurrence in jejunum at 5 years of follow up</td>
<td>1 postoperative wound infection, 1 biliary leak</td>
</tr>
<tr>
<td>Balladori⁷³</td>
<td>Pancreaticoduodenectomy</td>
<td>24 and 28 months 2 FAP</td>
<td>No recurrence</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Farnell⁶⁶</td>
<td>Pancreaticoduodenectomy</td>
<td>0.3–16 years (mean 5.6)</td>
<td>25 FAP and sporadic FAP patients</td>
<td>No recurrences</td>
<td>10 leaks, 4 delayed gastric emptying, 1 delirium tremens, 3 abscesses. 1 patient died from bleeding and sepsis related to hepatojejunoenterostomy leak. Morbidity was higher after pancreas sparing duodenotomy</td>
</tr>
</tbody>
</table>

*That is, anastomotic leakage, fistula formation, wound abscess, sepsis, or pancreatitis. NS, not stated; FAP, familial adenomatous polyposis.
三名患者发展出大息肉，一名发展出侵犯性治疗。在六个月或在药物停止后发展出的息肉。没有患者显示出息肉的退化；

跟进内镜检查为至少10个月。硫含酸在六名患者由于副作用而停止使用。

为残留的胰腺小腺瘤与硫含酸300 mg/day治疗。

在15名完成六个月的十二指肠腺瘤患者中，300 mg/day与钙和维生素D显示没有对胃及小肠腺瘤的影响。

根据Parker等人，用COX-2抑制剂罗非昔布25 mg/day，与硫酸脱氧胆酸的比较，没有在胃肠道腺瘤上显示出作用，也没有在胃肠道腺瘤数量及总面积。

一个14%的腺瘤数量减少。在六个患者中观察到2名患者与胃肠道腺瘤及尿酸性胃炎。

其他副作用包括：1名患者与胃肠道出血，1名患者与腹痛，1名患者与过敏反应。

Winde等人进行了一项前瞻性研究，非随机临床试验，对硫含酸50–300 mg/day进行剂量减少。

六名患者中，无在上消化道腺瘤上的作用。无在上消化道腺瘤数量上的作用。

改善了2名患者与胃肠道腺瘤及尿酸性胃炎。

终端效果

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment (dose/day)</th>
<th>Type of study</th>
<th>Duration</th>
<th>Patients</th>
<th>Outcome</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nugent &amp; Debinski</td>
<td>Sulindac 400 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>11</td>
<td>Number of polyps ↓ in 5 patients (p = 0.12 vs placebo). Second evaluation: effect on small polyps (≤2mm) (p = 0.02)</td>
<td>1 patient with indigestion</td>
</tr>
<tr>
<td>Seow-Choen</td>
<td>Sulindac 300 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>15</td>
<td>No effect</td>
<td>No adverse events reported</td>
</tr>
<tr>
<td>Richard</td>
<td>Sulindac 300 mg</td>
<td>Clinical trial</td>
<td>10–24 months</td>
<td>5</td>
<td>No regression of small residual polyps. 3 patients developed large polyps; 1 breakthrough carcinoma</td>
<td>2 patients with abdominal cramp, 1 patient with upper GI bleeding, 1 patient with allergic reaction, 1 patient with symptoms of dyspepsia, 2 patients with mild gastritis due to NSAID</td>
</tr>
<tr>
<td>Phillips</td>
<td>Celecoxib 800 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>30</td>
<td>Number of polyps ↓ compared to placebo (p = 0.03)</td>
<td></td>
</tr>
<tr>
<td>Winde</td>
<td>Sulindac 50–300 mg sup dose reduction</td>
<td>Prospective, controlled, non-randomised phase II dose finding study</td>
<td>Up to 4 years</td>
<td>xx</td>
<td>No effect on upper GI polyps</td>
<td></td>
</tr>
<tr>
<td>Maclean</td>
<td>Refecoxib 25 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>6</td>
<td>Improvement in 2 patients with stage III polyposis; no effect in 4 patients; no effect in ursodeoxycholic acid group</td>
<td></td>
</tr>
<tr>
<td>Parker</td>
<td>Sulindac 300 mg</td>
<td>Case report</td>
<td>5 and 14 years</td>
<td>1</td>
<td>No recurrence of duodenal polyps</td>
<td></td>
</tr>
<tr>
<td>Theodore</td>
<td>Sulindac 300–400 mg</td>
<td>Case reports</td>
<td>4.5–5 years</td>
<td>2</td>
<td>Sulindac normalised adenomatous ampulla and induced elimination of moderate dysplasia</td>
<td>No effect on gastric and small intestinal polyps</td>
</tr>
</tbody>
</table>

*The control group was treated with calcium and calciferol. The control group was treated with ursodeoxycholic acid. NSAID, non-steroidal anti-inflammatory drug.

300 mg/day与钙和钙化醇显示没有对十二指肠腺瘤的影响。

Richard和同事们治疗了8名FAP患者，患有残留的胰腺小腺瘤与硫含酸300 mg/day治疗，至少10个月。硫含酸在三名患者中由于副作用停止。内镜检查被进行，完成六个月或在中断治疗后。没有患者显示出腺瘤的退化；三名患者的腺瘤数目减少，一个在附着性腺瘤而未进行CIN。

一个随机化试验由Phillips和同事们，统计学上具有检测到小差异，研究了特定的COX-2抑制剂Celecoxib在十二指肠腺瘤数目及总面积的影响。腺瘤数目减少14%。在六个患者中观察到2名患者与胃肠道腺瘤及尿酸性胃炎。

终端效果

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment (dose/day)</th>
<th>Type of study</th>
<th>Duration</th>
<th>Patients</th>
<th>Outcome</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parker</td>
<td>Sulindac 400 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>11</td>
<td>Number of polyps ↓ in 5 patients (p = 0.12 vs placebo). Second evaluation: effect on small polyps (≤2mm) (p = 0.02)</td>
<td>1 patient with indigestion</td>
</tr>
<tr>
<td>Seow-Choen</td>
<td>Sulindac 300 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>15</td>
<td>No effect</td>
<td>No adverse events reported</td>
</tr>
<tr>
<td>Richard</td>
<td>Sulindac 300 mg</td>
<td>Clinical trial</td>
<td>10–24 months</td>
<td>5</td>
<td>No regression of small residual polyps. 3 patients developed large polyps; 1 breakthrough carcinoma</td>
<td>2 patients with abdominal cramp, 1 patient with upper GI bleeding, 1 patient with allergic reaction, 1 patient with symptoms of dyspepsia, 2 patients with mild gastritis due to NSAID</td>
</tr>
<tr>
<td>Phillips</td>
<td>Celecoxib 800 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>30</td>
<td>Number of polyps ↓ compared to placebo (p = 0.03)</td>
<td></td>
</tr>
<tr>
<td>Winde</td>
<td>Sulindac 50–300 mg sup dose reduction</td>
<td>Prospective, controlled, non-randomised phase II dose finding study</td>
<td>Up to 4 years</td>
<td>xx</td>
<td>No effect on upper GI polyps</td>
<td></td>
</tr>
<tr>
<td>Maclean</td>
<td>Refecoxib 25 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>6</td>
<td>Improvement in 2 patients with stage III polyposis; no effect in 4 patients; no effect in ursodeoxycholic acid group</td>
<td></td>
</tr>
<tr>
<td>Parker</td>
<td>Sulindac 300 mg</td>
<td>Case report</td>
<td>5 and 14 years</td>
<td>1</td>
<td>No recurrence of duodenal polyps</td>
<td></td>
</tr>
<tr>
<td>Theodore</td>
<td>Sulindac 300–400 mg</td>
<td>Case reports</td>
<td>4.5–5 years</td>
<td>2</td>
<td>Sulindac normalised adenomatous ampulla and induced elimination of moderate dysplasia</td>
<td>No effect on gastric and small intestinal polyps</td>
</tr>
</tbody>
</table>

*The control group was treated with calcium and calciferol. The control group was treated with ursodeoxycholic acid. NSAID, non-steroidal anti-inflammatory drug.

硫含酸300 mg/day与钙和钙化醇显示没有对十二指肠腺瘤的影响。

Richard和同事们研究了8名FAP患者，患有残留的胰腺小腺瘤与硫含酸300 mg/day治疗，至少10个月。硫含酸在三名患者中由于副作用停止。内镜检查被进行，完成六个月或在中断治疗后。没有患者显示出腺瘤的退化；三名患者的腺瘤数目减少，一个在附着性腺瘤而未进行CIN。

一个随机化试验由Phillips和同事们，统计学上具有检测到小差异，研究了特定的COX-2抑制剂Celecoxib在十二指肠腺瘤数目及总面积的影响。腺瘤数目减少14%。在六个患者中观察到2名患者与胃肠道腺瘤及尿酸性胃炎。

终端效果

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment (dose/day)</th>
<th>Type of study</th>
<th>Duration</th>
<th>Patients</th>
<th>Outcome</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parker</td>
<td>Sulindac 400 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>11</td>
<td>Number of polyps ↓ in 5 patients (p = 0.12 vs placebo). Second evaluation: effect on small polyps (≤2mm) (p = 0.02)</td>
<td>1 patient with indigestion</td>
</tr>
<tr>
<td>Seow-Choen</td>
<td>Sulindac 300 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>15</td>
<td>No effect</td>
<td>No adverse events reported</td>
</tr>
<tr>
<td>Richard</td>
<td>Sulindac 300 mg</td>
<td>Clinical trial</td>
<td>10–24 months</td>
<td>5</td>
<td>No regression of small residual polyps. 3 patients developed large polyps; 1 breakthrough carcinoma</td>
<td>2 patients with abdominal cramp, 1 patient with upper GI bleeding, 1 patient with allergic reaction, 1 patient with symptoms of dyspepsia, 2 patients with mild gastritis due to NSAID</td>
</tr>
<tr>
<td>Phillips</td>
<td>Celecoxib 800 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>30</td>
<td>Number of polyps ↓ compared to placebo (p = 0.03)</td>
<td></td>
</tr>
<tr>
<td>Winde</td>
<td>Sulindac 50–300 mg sup dose reduction</td>
<td>Prospective, controlled, non-randomised phase II dose finding study</td>
<td>Up to 4 years</td>
<td>xx</td>
<td>No effect on upper GI polyps</td>
<td></td>
</tr>
<tr>
<td>Maclean</td>
<td>Refecoxib 25 mg</td>
<td>Randomised controlled clinical trial</td>
<td>6 months</td>
<td>6</td>
<td>Improvement in 2 patients with stage III polyposis; no effect in 4 patients; no effect in ursodeoxycholic acid group</td>
<td></td>
</tr>
<tr>
<td>Parker</td>
<td>Sulindac 300 mg</td>
<td>Case report</td>
<td>5 and 14 years</td>
<td>1</td>
<td>No recurrence of duodenal polyps</td>
<td></td>
</tr>
<tr>
<td>Theodore</td>
<td>Sulindac 300–400 mg</td>
<td>Case reports</td>
<td>4.5–5 years</td>
<td>2</td>
<td>Sulindac normalised adenomatous ampulla and induced elimination of moderate dysplasia</td>
<td>No effect on gastric and small intestinal polyps</td>
</tr>
</tbody>
</table>

A case report描述了硫含酸300 mg/day防止了严重十二指肠腺瘤的复发。在FAP中。

另一个描述了两名患者，其治疗与硫含酸300–400 mg/day正常化了腺瘤性胰状及消除轻度染色。

相比之下，Waddell和同事们观察到硫含酸300–400 mg/day对胃肠道和小肠腺瘤在两名患者中。

在化学预防与NSAIDs，H2阻断剂和硫酸脱氧胆酸已被研究。

没有显著差异被发现在十二指肠腺瘤数量的增加或增加形成之间的ranitidine及安慰剂组。

在结论中，NSAID和其它化合物对Chemoprevention及Prevention of duodenal adenomas in FAP<br>appear disappointing, although regression of small adenomas may occur.

### MOLECULAR MECHANISMS OF CHEMOPREVENTION WITH NSAIDS

Studies of chemoprevention/regression of duodenal polyps in FAP have primarily utilised NSAIDs. The action of these agents has been divided into COX dependent, mediated through inhibition of the COX enzymes, and COX independent, caused by direct actions of NSAIDs on different molecular mechanisms.

**COX dependent mechanisms**

NSAIDs are best known for inhibitory effects on COX-1 and COX-2, key enzymes in the conversion of arachidonic acid to prostaglandins (PGs) (fig 5). COX-1 expression occurs in...
most tissues whereas COX-2 is expressed in response to growth factors, lipopolysaccharide, cytokines, mitogens, and tumour promoters. PGs are involved in cellular functions such as angiogenesis and cell proliferation. Therefore, inhibition of PG synthesis could explain part of the antineoplastic effects of NSAIDs. Also, COX-2 inhibition has antiangiogenic effects, as confirmed by several different studies. COX-2 inhibition may also induce apoptosis, mainly via inhibition of PGE2, and inhibit invasive properties of cancer cells. COX-2 was induced by coculture and promoted invasion in vitro that was inhibited by NSAIDs or RNAi against COX-2.

**COX independent mechanisms**

Several lines of evidence support the importance of COX independent means of action of NSAIDs. Firstly, high doses of NSAIDs induce apoptosis in COX-1 or COX-2 deficient cell lines and, secondly, PGs do not rescue these cells from apoptosis.

Various COX-2 independent targets for NSAIDs have been proposed (fig 6). β-Catenin appears to be an important target as both indomethacin and exisulind reduce β-catenin expression in colorectal cancer cells. Also, NSAIDs induce apoptosis via both the membrane bound and mitochondrial pathway. High doses of aspirin antagonise the transcription factor nuclear factor kB, which regulates expression of antiapoptotic genes encoding proteins such as TRAF, c-IAP, c-FLIP, Bcl-XL, and A1. Several studies indicate a role for proteins of the Bcl-2 family in the apoptotic response to NSAIDs, and the membrane death receptor apoptotic pathway may also be involved. Furthermore, TGF-β signalling is implicated in NSAID chemoprevention. NSAIDs affect cell adhesion and lipoxigenase metabolism, which reduce colorectal cancer cell invasion and could explain part of the apoptotic response to NSAIDs in colorectal cancer cells. Finally, it appears that members of the peroxisome proliferator activated receptor (PPAR) family, PPARδ and PPARγ, are directly targeted by NSAIDs and PGs.

**CONCLUSIONS AND FUTURE DIRECTIONS**

With improvement in the management of colorectal disease and increased life expectancy, duodenal polyposis and malignancy have emerged as major health problems in patients with FAP. Although most patients eventually develop duodenal polyps, these lesions occur at later age and have lower potential for malignant change compared with colonic polyps. Moreover, duodenal adenomas seem less responsive to chemoprevention with NSAIDs than colonic counterparts.

Currently, the main treatment options for duodenal polyposis are frequent surveillance and targeted endoscopic treatment, adjusted by severity of duodenal lesions. However, these modalities alone cannot guarantee a polyp-free duodenum. In patients with severe disease, duodenotomy or duodenectomy may be necessary. Drug therapy of duodenal adenomas would be appropriate treatment but...
most published reports find no significant effect of NSAIDs or COX-2 inhibitors on duodenal adenoma regression.

Increasing insights into the molecular changes during the adenoma-carcinoma sequence in the duodenum may point to future treatment strategies. Duodenal mucosa is exposed to different environmental factors than that in the colon. Low pH and bile acids may affect control of growth and malignant potential of duodenal tumours.12-14 Little is known about the role of potential molecular targets for chemoprevention, including COX-2, PPARα, TGF-β receptor type II, EGF-R, and inducible nitric oxide synthase. More powerful chemopreventive/regressive regimens could result from combinations of NSAIDs or COX-2 inhibitors with other drugs, such as selective inhibitors of receptor tyrosine kinases or EGF-R. Further study is needed to understand the molecular changes in duodenal adenoma development and identify molecular targets for chemoprevention and regression of duodenal polyposis.

ACKNOWLEDGEMENTS

Supported in part by the Queen Wilhelmina Fund/Dutch Cancer Society, the John G Rangos Sr Charitable Foundation, the Clayton Fund, and NIH grants 3S801, 63721, 51085, and P50 CA 93–16.

Authors’ affiliations

L A A Brosens, Departments of Pathology, Medicine, and Oncology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands

J J Keller, G J A Offerhaus, Department of Medicine, the Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands

M Goggins, P M Giardiello, Departments of Pathology, Medicine, and Oncology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA

Conflict of interest: None declared.

REFERENCES

1 Trimbath JD, Giardiello FM. Review article: genetic testing and counseling for hereditary colorectal cancer. Aliment Pharmacol Ther 2002;16:1843–57


Prevention and management of duodenal polyps in familial adenomatous polyposis

L A A Brosens, J J Keller, G J A Offerhaus, M Goggins and F M Giardiello

Gut 2005 54: 1034-1043
doi: 10.1136/gut.2004.053843

Updated information and services can be found at:
http://gut.bmj.com/content/54/7/1034

These include:

References
This article cites 89 articles, 26 of which you can access for free at:
http://gut.bmj.com/content/54/7/1034#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Colon cancer (1547)
- Cancer: small intestine (189)
- Hepatic cancer (474)
- Pancreatic cancer (660)
- Pancreas and biliary tract (1949)
- Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/